MyFinsight
Home
Blog
About
Contact
Download
Download image
Syfovre
$150,719K
(15.78%↑ Y/Y)
Empaveli Pegcetacoplan
$41,291K
(109.32%↑ Y/Y)
Product
$192,010K
(28.09%↑ Y/Y)
Licensing And Other
Revenue
$76,285K
(351.47%↑ Y/Y)
Revenue
$268,295K
(60.85%↑ Y/Y)
Net operating
income/(gain)
$26,467K
(131.76%↑ Y/Y)
Interest income
$2,914K
(9.63%↑ Y/Y)
Other
income/(expense), net
$88K
(153.33%↑ Y/Y)
Total operating
expenses
$241,828K
(-3.32%↓ Y/Y)
Net income/(gain)
before taxes
$19,152K
(120.84%↑ Y/Y)
Interest expense
$10,317K
(-6.63%↓ Y/Y)
Selling, general and
administrative
$124,323K
(-3.88%↓ Y/Y)
Research and development
$76,958K
(-10.95%↓ Y/Y)
Cost of sales
$40,547K
(18.01%↑ Y/Y)
Net income/(gain)
$18,656K
(120.23%↑ Y/Y)
Income tax expense
$496K
(45.45%↑ Y/Y)
Comprehensive income/(gain),
net of tax
$18,348K
(119.95%↑ Y/Y)
Total other
comprehensive income/(loss)
-$308K
(-221.26%↓ Y/Y)
Foreign currency
translation
-$308K
(-221.26%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)